66735-01-1

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-bromobenzyl)propanoic acid is used as a building block for the synthesis of various drugs and pharmaceuticals, due to its unique structure and functional groups that can be further modified or incorporated into more complex molecules.
Used in Organic Chemistry:
2-(4-bromobenzyl)propanoic acid is used as a starting material for the preparation of other organic compounds, taking advantage of its reactive bromine atom and benzyl group for various chemical reactions and transformations.
Used in Biochemistry:
2-(4-bromobenzyl)propanoic acid has potential applications in biochemistry as a starting material for the preparation of biologically active compounds, given its potential to be modified or functionalized for specific interactions with biological systems.
Used in Research and Development:
2-(4-bromobenzyl)propanoic acid may be studied for its potential pharmacological properties, including biological activity, as it could provide insights into the development of new therapeutic agents or contribute to the understanding of molecular mechanisms in biological processes.

Upstream product

• 70146-85-9 2-(4-bromobenzyl)-2-methylmalonic acid diethyl ester 
• 802294-64-0 propionic acid 
• 589-15-1 1-bromomethyl-4-bromobenzene 
• 66735-14-6 4-Brom-α-methyl-zimtsaeure 

Downstream Products

• 186497-72-3 2-methyl-3-(4-bromophenyl)propanol 

Relevant academic research and scientific papers

Palladium-Catalyzed C(sp3)-H Nitrooxylation with tert-Butyl Nitrite and Molecular Oxygen

Herein, we report a Pd(II)-catalyzed nitrooxylation of unactivated methyl C(sp3)-H bonds using commercial available and easily manageable tert-butyl nitrite as the precursor of ONO2 radical under aerobic conditions. Environmentally benign molecular oxygen is used to initiate the generation of active radical reactant; it is also used as the terminal oxidant. A broad range of nitrooxylated aliphatic carboxamides were prepared in moderate to good yields under mild conditions.

Cobalt-Catalyzed Asymmetric Hydrogenation of α,β-Unsaturated Carboxylic Acids by Homolytic H2 Cleavage

The asymmetric hydrogenation of α,β-unsaturated carboxylic acids using readily prepared bis(phosphine) cobalt(0) 1,5-cyclooctadiene precatalysts is described. Di-, tri-, and tetra-substituted acrylic acid derivatives with various substitution patterns as well as dehydro-α-amino acid derivatives were hydrogenated with high yields and enantioselectivities, affording chiral carboxylic acids including Naproxen, (S)-Flurbiprofen, and a d-DOPA precursor. Turnover numbers of up to 200 were routinely obtained. Compatibility with common organic functional groups was observed with the reduced cobalt(0) precatalysts, and protic solvents such as methanol and isopropanol were identified as optimal. A series of bis(phosphine) cobalt(II) bis(pivalate) complexes, which bear structural similarity to state-of-the-art ruthenium(II) catalysts, were synthesized, characterized, and proved catalytically competent. X-band EPR experiments revealed bis(phosphine)cobalt(II) bis(carboxylate)s were generated in catalytic reactions and were identified as catalyst resting states. Isolation and characterization of a cobalt(II)-substrate complex from a stoichiometric reaction suggests that alkene insertion into the cobalt hydride occurred in the presence of free carboxylic acid, producing the same alkane enantiomer as that from the catalytic reaction. Deuterium labeling studies established homolytic H2 (or D2) activation by Co(0) and cis addition of H2 (or D2) across alkene double bonds, reminiscent of rhodium(I) catalysts but distinct from ruthenium(II) and nickel(II) carboxylates that operate by heterolytic H2 cleavage pathways.

Heterocyclic compounds

The invention concerns pharmaceutically useful compounds of the formula I, in which A1, A2, A3, A4, B1, m, Ar, W, X, Y, Z and R1 have any of the meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel compounds possess endothelin receptor antagonist activity and are useful, for example, in the treatment of diseases or medical conditions in which elevated or abnormal levels of endothelin play a significant causative role. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.